Alkermes PLC is a fully integrated biotechnology company that applies its proprietary technologies to research, develop, and commercialize pharmaceutical products designed for unmet medical needs in therapeutic areas. The company utilizes several to develop and commercialize products and, in so doing, access technological, financial, marketing, manufacturing, and other resources. Alkermes either purchases active drug products from third parties or receives them from its third-party licensees to formulate products using its technologies. It operates in U.S., which derives maximum revenue, Ireland and Rest of the world.
Last trade$45.45
Day change-$1.08 (-2.32%)
Day range$45.10 – $46.68
Volume368,619
Market cap$7.82B
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$7.82B
Price / earnings
—
Price / book
4.19×
Price / sales
4.46×
EV / sales
4.95×
EV / EBITDA
35.64×
Profitability
Earnings per share
-$0.00
Return on assets
-0.01%
Return on equity
-0.02%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0.8×
Current ratio
2.42×
Quick ratio
2.02×
Cash ratio
0.97×
Cash flow
Price / cash flow
32.18×
Price / free cash flow
34.39×
Free cash flow
$227.37M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for ALKS, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$480.13M
$496.01M
$392.91M
$384.55M
$394.19M
$390.66M
$306.51M
$429.99M
Cost of revenue
$94.22M
$98.11M
$61.58M
$46.21M
$51.59M
$49.46M
$49.2M
$62.12M
Gross profit
$385.91M
$397.9M
$331.33M
$338.34M
$342.59M
$341.2M
$257.31M
$367.87M
Selling, general and administrative
$208.5M
$217.63M
$264.59M
$187.2M
$171.77M
$170.85M
$171.7M
$146.99M
Research and development
$121.12M
$112.92M
$103.35M
$93.04M
$81.74M
$77.37M
$71.82M
$58.17M
Total operating expenses
$349.89M
$379.54M
$379.61M
$280.23M
$253.51M
$248.22M
$243.52M
$205.18M
Operating income
$36.02M
$18.35M
-$48.28M
$58.1M
$89.08M
$92.98M
$13.79M
$162.69M
Interest expense
-$27.55M
-$25.93M
-$20.89M
-$12.28M
$0
$0
$0
-$4.65M
Income before taxes
$14.74M
-$1.88M
-$61.93M
$60.38M
$100.75M
$104.84M
$25.49M
$169.89M
Income taxes
-$1.55M
-$2.38M
$4.55M
$11.04M
$17.98M
$17.74M
$3.03M
$24.15M
Net income
$16.29M
$501K
-$66.48M
$49.34M
$82.76M
$87.1M
$22.46M
$146.5M
Net income attributable to common shareholders
$16.29M
$501K
-$66.48M
$49.34M
$82.76M
$87.1M
$22.46M
$146.5M
EBITDA
$135.58M
$75.04M
-$28.85M
$61.95M
$97.16M
$100.8M
$21.21M
$169.54M
Basic earnings per share
$0.10
$0.00
-$0.40
$0.30
$0.50
$0.53
$0.14
$0.90
Diluted earnings per share
$0.09
$0.00
-$0.40
$0.29
$0.49
$0.52
$0.13
$0.88
Recent news
Company coverage with links to the original publishers.
Tarsus Pharmaceuticals is expected to report a quarterly loss of $1.43 per share (down 376.7% YoY) with revenues of $188.8 million (up 59.1% YoY) for Q3 2026. The company has a negative Earnings ESP of -40.31% combined with a Zacks Rank #2, making it unlikely to beat consensus estimates. The company has a mixed earnings surprise history, beating estimates in 2 of the last 4 quarters.
Harmony Biosciences (HRMY) has outperformed the market with a 27.6% share surge over six months, driven by robust Wakix sales growth of 24% to $476.7 million in H1 2026 and promising pipeline candidates BP-205 and EPX-100. The company maintains its $1.0-$1.04B full-year revenue guidance and has $962.5M in cash to fund development. However, competition from Jazz Pharmaceuticals' Xywav and Alkermes' Lumryz, along with patent litigation risks, present headwinds.
Four central nervous system (CNS) pharmaceutical companies—Axsome Therapeutics, Neurocrine Biosciences, Alkermes, and Acadia Pharmaceuticals—are highlighted as relevant investment opportunities ahead of World Mental Health Day. All four companies carry a Zacks Rank #3 (Hold) rating and have strong CNS portfolios with meaningful revenue growth in H1 2026, supported by expanding pipelines addressing psychiatric and neurological disorders.
The global substance use disorder treatment market is projected to grow from $11.6 billion in 2025 to $14.6 billion by 2030, with a compound annual growth rate of 4.6%. Growth is driven by long-acting therapies, telemedicine expansion, drug innovation, and increased government interventions, though challenges include low treatment penetration and stigma.
Alkermes announced positive top-line results from a phase I proof-of-concept study of ALKS 7290, an orexin 2 receptor agonist for ADHD treatment. The drug demonstrated dose-dependent, clinically meaningful improvements in ADHD symptoms with median AISRS score reductions of 14-19 points and was well tolerated with no serious adverse effects. Phase II studies are ongoing with data expected in 2027.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.